Chinese API Manufacturer Expands International Presence, Provides Funding For U.S. Startup
This article was originally published in PharmAsia News
Executive Summary
Venture funds are expanding throughout Asia, and government groups are establishing funds to draw business, but there are also signs that Asian pharmaceutical firms are looking to invest in Western startups and are turning their gaze beyond their own borders
You may also be interested in...
Pfizer Looks To Ramp Up Branded Generics Via MOU With China's Hisun
Pfizer Inc. and Shanghai-based Zhejiang Hisun Pharmaceuticals announced June 2 a memorandum of understanding to potentially establish a joint venture to develop, manufacture and sell branded generics in China and other markets
Pfizer Looks To Ramp Up Branded Generics Via MOU With China's Hisun
Pfizer Inc. and Shanghai-based Zhejiang Hisun Pharmaceuticals announced June 2 a memorandum of understanding to potentially establish a joint venture to develop, manufacture and sell branded generics in China and other markets
Pfizer Looks To Ramp Up Branded Generics Via MOU With China's Hisun
Somewhat similar to Pfizer's recent agreement with Shanghai Pharmaceuticals Holdings, the deal will focus on manufacturing and broader commercialization of medicines.